Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: Very low risk for subsequent breast cancer

Annals of Surgery

Volumn 251, Issue 3, 2010, Pages 488-492

  Kaas, Reinoutje ^a   Verhoef, Senno ^a   Wesseling, Jelle ^a   Rookus, Matti A ^a   Oldenburg, Hester S A ^a   Peeters, Marie Jeanne Vrancken ^a   Rutgers, Emiel J T ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER STAGING; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; SALPINGOOOPHORECTOMY; SCREENING;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY; MIDDLE AGED; MUTATION; RISK FACTORS;

EID: 77649139906     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181c3c36d     Document Type: Article

References (27)

1. Ford D, Easton DF, Bishop DT, et al; Breast Cancer Linkage Consortiun. Risks of cancer in BRCA1 mutation carriers. Lancet. 1994;343:692-695.
2. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Human Genet. 1998;62:676-689.
3. Robson M, Offit K. Management of inherited predisposition of breast cancer. N Engl J Med. 2007;357:154-162.
4. Evans DG, Shenton A, Woodward E, et al. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer. 2008;8:155.
5. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2004;22:1055-1062. (Pubitemid 41095038)
6. Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007;14:3335-3344.
7. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94:1365-1372.
8. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310-1316.
9. Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006;24:2437-2443.
10. Haffty BG, Harrold E, Khan AF, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002;359:1471-1477.
11. Sprundel TC van, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2005;93:287-292.
12. Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol. 2005;23:4275-4286.
13. McDonnell SK, Schaid DJ, Myers JL, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19:3938-3943.
14. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. JAMA. 1997;227:997-1003.
15. Antoniou A, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: update and extensions. BJC. 2008;1-10.
16. Olivier RI, Beurden M van, Lubsen MA, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer. 2004;90:1492-1497.
17. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633-1637.
18. Kauff ND, Brogi E, Scheuer L, et al. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer. 2003; 97:1601-1608.
19. Hoogerbrugge N, Bult P, Bonenkamp JJ, et al. Numerous high-risk epithelial lesions in familial breast cancer. Eur J Cancer. 2006;42:2492-2498.
20. Dupont EL, Kuhn A, McCann C, et al. The role of sentinel lymph node biopsy in women undergoing prophylactic mastectomy. Am J Surg. 2000;180:274-277.
21. McLaughlin SA, Stempel M, Morris EA, et al. Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy? Cancer. 2008;112:1214-1221.
22. Boughey JC, Khakpour N, Meric-Bernstam F, et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006;107: 1440-1447.
23. Black D, Specht M, Lee JM, et al. Detect occult malignancy in prophylactic mastectomy: preoperative MRI versus sentinel lymp node biopsy. Ann Surg Oncol. 2007;14:2477-2484.
24. Soran A, Falk J, Bonaventura M, et al. Is routine lymph node biopsy indicated in women undergoing contralateral prophylactic mastectomy? Magee-wom-ens hospital experience. Ann Surg Oncol. 2006;14:646-651.
25. Verhoog LC, Brekelmans CT, Seynave C, et al. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer. 2000;83:384-386.
26. Smith KL, Adank M, Kauff N, et al. BRCA mutations in women with ductal carcinoma in situ. Clin Cancer Res. 2007;13:4306-4310.
27. Kaas R, Muller SH, Hart AA, et al. Stage of breast cancers found during the surveillance of women with a familial or hereditary risk. Eur J Surg Oncol. 2008;34:501-507.